tbuckley/cabot-search huggingface dataset:
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
Authors: Francesco Marchesi, Jon Salmanton-García, Caterina Buquicchio, Federico Itri, Caroline Besson, Julio Dávila-Valls, Sonia Martín-Pérez, Luana Fianchi, Laman Rahimli, Giuseppe Tarantini, Federica Irene Grifoni, Mariarita Sciume, Jorge Labrador, Raul Cordoba, Alberto López-García, Nicola S. Fracchiolla, Francesca Farina, Emanuele Ammatuna, Antonella Cingolani, Daniel García-Bordallo, Stefanie K. Gräfe, Yavuz M. Bilgin, Michelina Dargenio, Tomás José González-López, Anna Guidetti, Tobias Lahmer, Esperanza Lavilla-Rubira, Gustavo-Adolfo Méndez, Lucia Prezioso, Martin Schönlein, Jaap Van Doesum, Dominik Wolf, Ditte Stampe Hersby, Ferenc Magyari, Jens Van Praet, Verena Petzer, Carlo Tascini, Iker Falces-Romero, Andreas Glenthøj, Oliver A. Cornely, Livio Pagano
Journal: Journal of Hematology & Oncology (2023)

Abstract Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDEHA registry). We identified 47 patients that had received prophylaxis with tixagevimab/cilgavimab in the EPICOVIDEHA registry. Lymphoproliferative disorders (44/47, 93.6%) were the main underlying HM. SARS-CoV-2 strains were genotyped in 7 (14.9%) cases only, and all belonged to the omicron variant. Forty (85.1%) patients had received vaccinations prior to tixagevimab/cilgavimab, the majority of them with at least two doses. Eleven (23.4%) patients had a mild SARS-CoV-2 infection, 21 (44.7%) a moderate infection, while 8 (17.0%) had severe infection and 2 (4.3%) critical. Thirty-six (76.6%) patients were treated, either with monoclonal antibodies, antivirals, corticosteroids, or with combination schemes. Overall, 10 (21.3%) were admitted to a hospital. Among these, two (4.3%) were transferred to intensive care unit and one (2.1%) of them died. Our data seem to show that the use of tixagevimab/cilgavimab may lead to a COVID-19 severity reduction in HM patients; however, further studies should incorporate further HM patients to confirm the best drug administration strategies in immunocompromised patients.
After PSA screening, MRI-targeted vs. systematic biopsy detected fewer clinically insignificant prostate cancers
Authors: Richard M. Hoffman
Journal: Annals of Internal Medicine (2023)

ACP Journal Club4 April 2023After PSA screening, MRI-targeted vs. systematic biopsy detected fewer clinically insignificant prostate cancersRichard M. Hoffman, MD, MPHRichard M. Hoffman, MD, MPHUniversity of Iowa Carver College of Medicine, Iowa City, Iowa, USA (R.M.H.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/J23-0017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationHugosson J, Månsson M, Wallström J, et al. Prostate cancer screening with PSA and MRI followed by targeted biopsy only. N Engl J Med. 2022;387:2126-37. https://pubmed.ncbi.nlm.nih.gov/36477032Clinical Impact RatingsGIM/FP/GP: Oncology: References1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer early detection. Version 1.2023. 9 Jan 2023. Accessed at www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf on 23 Jan 2023. Google Scholar2. Booker MT, Silva E 3rd, Rosenkrantz AB. National private payer coverage of prostate MRI. J Am Coll Radiol. 2019;16:24-9. [PMID: 30213713] Google Scholar3. Quinn TP, Sanda MG, Howard DH, et al. Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer. Cancer. 2021;127:2974-9. [PMID: 34139027] Google Scholar4. Hoffman RM, Mott SL, McDowell BD, et al. Trends and practices for managing low-risk prostate cancer: a SEER-Medicare study. Prostate Cancer Prostatic Dis. 2022;25:100-8. [PMID: 34108645] Google Scholar Author, Article, and Disclosure InformationAuthors: Richard M. Hoffman, MD, MPHAffiliations: University of Iowa Carver College of Medicine, Iowa City, Iowa, USA (R.M.H.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=J23-0017.This article was published at Annals.org on 4 April 2023.ACP Journal Club is editorially independent from Annals of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics April 2023Volume 176, Issue 4 Page: JC44 Keywords Antigens Biopsy Cancer screening Lesions Magnetic resonance imaging Overdiagnosis Population statistics Prostate cancer Transrectal ultrasound ePublished: 4 April 2023 Issue Published: April 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Mindfulness Training and Exercise and Cognitive Function in Older Adults—Reply
Authors: Eric J. Lenze, Elizabeth W. Twamley, Julie Loebach Wetherell
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Development of a Synthetic, Injectable Hydrogel to Capture Residual Glioblastoma and Glioblastoma Stem‐Like Cells with CXCL12‐Mediated Chemotaxis
Authors: Zerin Mahzabin Khan, Jennifer M. Munson, Timothy E. Long, Eli Vlaisavljevich, Scott S. Verbridge
Journal: Advanced Healthcare Materials (2023)

Glioblastoma (GBM), characterized by high infiltrative capacity, is the most common and deadly type of primary brain tumor in adults. GBM cells, including therapy-resistant glioblastoma stem-like cells (GSCs), invade the healthy brain parenchyma to form secondary tumors even after patients undergo surgical resection and chemoradiotherapy. New techniques are therefore urgently needed to eradicate these residual tumor cells. A thiol-Michael addition injectable hydrogel for compatibility with GBM therapy is previously characterized and optimized. This study aims to develop the hydrogel further to capture GBM/GSCs through CXCL12-mediated chemotaxis. The release kinetics of hydrogel payloads are investigated, migration and invasion assays in response to chemoattractants are performed, and the GBM-hydrogel interactions in vitro are studied. With a novel dual-layer hydrogel platform, it is demonstrated that CXCL12 released from the synthetic hydrogel can induce the migration of U251 GBM cells and GSCs from the extracellular matrix microenvironment and promote invasion into the synthetic hydrogel via amoeboid migration. The survival of GBM cells entrapped deep into the synthetic hydrogel is limited, while live cells near the surface reinforce the hydrogel through fibronectin deposition. This synthetic hydrogel, therefore, demonstrates a promising method to attract and capture migratory GBM cells and GSCs responsive to CXCL12 chemotaxis.
FDA Oncology Center of Excellence Crowdsourcing Initiative: Outreach to the Scientific Community to Identify Research Questions for Pooled Analyses of Oncology Clinical Trial Data
Authors: Julie A. Schneider, Julia Eckstein, Kirsten B. Goldberg, Mark C. Ascione, Thamar Bailey, Kimberly Taylor, Aisha M. Coffey, Darshini Satchi, Howard Philips, Rajeshwari Sridhara, Abhilasha Nair, Richard Pazdur, Marc R. Theoret
Journal: Clinical Cancer Research (2023)

Abstract The FDA Oncology Center of Excellence recently launched a crowdsourcing pilot to request ideas from the scientific community for research questions that FDA could address with pooled analyses of clinical trial data submitted to the agency for regulatory purposes. This effort builds on FDA's track record of publishing pooled analyses to explore scientific questions that cannot be addressed in a single trial due to limited sample size. The research crowdsourcing pilot tested a new approach for obtaining external input on regulatory science activities, because FDA is generally unable to share patient-level data outside of the agency due to federal disclosure laws and regulations protecting different types of data submitted in regulatory applications. We received 29 submissions over the 28-day crowdsourcing campaign, including one research idea that we are exploring for possible follow-up. Based on our experience with this pilot, we learned that crowdsourcing is a promising new approach to gather external input and feedback. We identified opportunities to build understanding in the external oncology community about the types of data typically included in regulatory applications and expand the dissemination of published FDA pooled analyses to help inform future drug development and clinical practice.
In critically ill patients with COVID-19, IL-6 receptor antagonists reduced mortality vs. control at 180 d
Authors: Charlotte Fuller, Zain Chagla
Journal: Annals of Internal Medicine (2023)

Source Citation Writing Committee for the REMAP-CAP Investigators; Higgins AM, Berry LR, Lorenzi E, et al. Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial. JAMA. 2023;329:39-51. 36525245
Moral Distress as Critique: Going beyond ‘Illegitimate Institutional Constraints’
Authors: Kate Jackson-Meyer, Xavier Symons, Charlotte Duffee
Journal: The American Journal of Bioethics (2023)

Click to increase image sizeClick to decrease image sizeThis article refers to:Moral Distress: What Are We Measuring? DISCLOSURE STATEMENTNo potential conflict of interest was reported by the author(s).Additional informationFundingThe author(s) reported there is no funding associated with the work featured in this article.
Evolving Measures of Moral Distress: Imperfect Does Not Mean Irrelevant
Authors: Lucia D. Wocial
Journal: The American Journal of Bioethics (2023)

Click to increase image sizeClick to decrease image sizeThis article refers to:Moral Distress: What Are We Measuring? DISCLOSURE STATEMENTNo potential conflict of interest was reported by the author(s).Additional informationFundingThe author(s) reported there is no funding associated with the work featured in this article.
ROS-activatable nanocomposites for CT imaging tracking and antioxidative protection of mesenchymal stem cells in idiopathic pulmonary fibrosis therapy
Authors: Yinjuan Lv, Chenggong Yu, Xiaodi Li, Hongying Bao, Shaoshuai Song, Xiaoling Cao, Haixia Lin, Jie Huang, Zhijun Zhang
Journal: Journal of Controlled Release (2023)
CD73 Is a Critical Immune Checkpoint in a Molecular Subtype of Pancreatic Cancer
Authors: Kathleen DelGiorno
Journal: Cancer Research (2023)

Abstract Molecular stratification of patients with pancreatic ductal adenocarcinoma (PDAC) has the potential to guide clinical decision-making for therapeutic intervention. Investigating mechanisms by which different molecular subtypes of PDAC form and progress will improve patient responses to existing therapies and aid in identifying new, more specific therapeutic approaches. In this issue of Cancer Research, Faraoni and colleagues identified CD73/Nt5e-generated adenosine as a mechanism of immunosuppression specifically in pancreatic ductal–derived basal/squamous-type PDAC. Using genetically engineered mouse models targeting key genetic mutations to pancreatic acinar or ductal cells and an array of experimental and computational biology approaches, the authors found that adenosine signaling through receptor ADORA2B induces immunosuppression and tumor progression in ductal cell–derived tumors. These data demonstrate how molecular stratification of PDAC in combination with targeted approaches may enhance patient responses to therapy in this deadly cancer. See related article by Faraoni et al., p. 1111
The SCARE 2023 guideline: updating consensus Surgical CAse REport (SCARE) guidelines
Authors: Catrin Sohrabi, Ginimol Mathew, Nicola Maria, Ahmed Kerwan, Thomas Franchi, Riaz A Agha
Journal: International Journal of Surgery (2023)

The Surgical CAse REport (SCARE) guidelines were first published in 2016 as a tool for surgeons to document and report their surgical cases in a standardised and comprehensive manner. However, with advances in technology and changes in the healthcare landscape, it is important to revise and update these guidelines to ensure they remain relevant and valuable for surgeons.The updated guidelines were produced through a Delphi consensus exercise. Members of the SCARE 2020 guidelines Delphi group, editorial board members, and peer reviewers were invited to participate. Potential contributors were contacted by e-mail. An online survey was completed to indicate their agreement with the proposed changes to the guideline items.A total of 54 participants were invited to participate and 44 (81.5%) completed the survey. There was a high degree of agreement among reviewers, with 36 items (83.7%) meeting the threshold for inclusion.Through a completed Delphi consensus exercise we present the SCARE 2023 guidelines. This will provide surgeons with a comprehensive and up-to-date tool for documenting and reporting their surgical cases while highlighting the importance of patient-centred care.
CAR T-Cell therapy for the management of mantle cell lymphoma
Authors: Zoufang Huang, Vivek P. Chavda, Rajashri Bezbaruah, Hemant Dhamne, Dong-Hua Yang, Hong-Bing Zhao
Journal: Molecular Cancer (2023)

Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma (NHL) of mature B-cells characterized by translocation, which is typically due to excess expression of Cyclin D1. Although with the progress in our knowledge of the causes for MCL and available treatments for MCL, this cancer is still incurable. Age, male gender, rapid advancement, significant nodal involvement, elevated serum lactate dehydrogenase level, and prognostic indications including increased expression of Ki-67 and presence of TP53 mutation, are symbols of poor outcome. Advanced immunotherapy using chimeric antigen receptor (CAR)-T cells is advantageous for patients suffering from B-cell malignancies and MCL. Targeting B-cell antigens on the cell surface is a feasible approach in re-occurring (R/R) MCL because of significant responses obtained in other B-cell cancers. USFDA has approved brexucabtagene autoleucel (Tecartus, KTE-X19), a novel CAR T-cell therapy to be used in patients with MCL who have not responded to previous treatments or have relapsed. The FDA approved this new treatment depending on the outcomes of the ZUMA-2 clinical trial. Serious adverse reactions, moderate anti-tumor activity, allergen withdrawal, antigen escape, limited tumor infiltration, and trafficking are major barriers to successful CAR T-cell therapy. This review is a brief synopsis of the development of CAR T-cell therapy for MCL.
ADCs or: How I Learned to Stop Worrying and Love Chemotherapy
Authors: Avantika Gupta, Joshua Z. Drago, Sarat Chandarlapaty
Journal: Cancer Discovery (2023)

Summary: Antibody–drug conjugates are transforming cancer treatment, and payload characteristics are emerging as crucial determinants of clinical activity. As exemplified by Weng and colleagues, advancements in the linker and payload chemistry may provide the next evolutionary step in enabling this class of drugs to overcome chemoresistance and deliver even more profound responses. See related article by Weng et al., p. 950 (2).
Birth Outcomes Following Assisted Reproductive Technology Conception Among Same-Sex Lesbian Couples vs Natural Conception and Assisted Reproductive Technology Conception Among Heterosexual Couples
Authors: Alice Goisis, Agneta Cederström, Pekka Martikainen
Journal: JAMA (2023)

This study uses registry data to compare birth outcomes, including birth weight, gestational age, low birth weight, and preterm delivery, in assisted reproductive technology (ART) pregnancies among same-sex lesbian couples vs natural conceptions and ART pregnancies among heterosexual couples.
Ethics Debriefs and Moral Distress: What are we Doing?
Authors: A. Lee de Bie, Steve Abdool, Jeremy Butler, Alexandra Campbell, Maram Hassanein, Sean Hillman, Juhee Makkar, Rochelle Maurice, Jamie Robertson, Michael J. Szego, Dave Langlois
Journal: The American Journal of Bioethics (2023)

Click to increase image sizeClick to decrease image sizeThis article refers to:Moral Distress: What Are We Measuring? Additional informationFundingThe author(s) reported there is no funding associated with the work featured in this article.
Medicare Advantage vs Traditional Medicare and 30-Day Mortality in Patients With AMI—Reply
Authors: Bruce E. Landon, Vilsa Curto, John Z. Ayanian
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
On-the-Go Adaptation of Implementation Approaches and Strategies in Health: Emerging Perspectives and Research Opportunities
Authors: Elvin H. Geng, Aaloke Mody, Byron J. Powell
Journal: Annual Review of Public Health (2023)

In many cases, implementation approaches (composed of one or more strategies) may need to change over time to work optimally. We use a literature review to inform a mechanistic analysis of such on-the-go adaptations. We suggest that such adaptations of implementation strategies consist of three necessary steps. The first component is the initial effect of the implementation approach on intended implementation, service delivery, or clinical outcomes. Second, these initial effects must in turn be used to modify, alter, intensify, or otherwise change the implementation approach. Third, the modified approach itself has effects. Conceiving of adaptation as all three steps implies that a full understanding of adaptation involves ( a) a sense of initial effects, ( b) conceptualizing and documenting content and rationale for changes in approach (e.g., alteration, intensification), and ( c) the effects of the changed approach (including how the latter effects depend on initial effects). Conceptualizing these steps can help researchers ask questions about adaptation (e.g., thresholds for change, dosing, potentiation, sequencing) to advance our understanding of implementation strategies.
PARP1 negatively regulates MAPK signaling by impairing BRAF-X1 translation
Authors: Andrea Marranci, Antonella Prantera, Simona Masotti, Raffaella De Paolo, Caterina Baldanzi, Maurizio S. Podda, Serena Mero, Marianna Vitiello, Cinzia Franchin, Mariavittoria Laezza, Laura Comelli, Giorgio Arrigoni, Tiziana Cervelli, Giovanna Del Pozzo, Laura Poliseno
Journal: Journal of Hematology & Oncology (2023)

Abstract In human cells BRAF oncogene is invariably expressed as a mix of two coding transcripts: BRAF-ref and BRAF-X1 . These two mRNA isoforms, remarkably different in the sequence and length of their 3′UTRs , are potentially involved in distinct post-transcriptional regulatory circuits. Herein, we identify PARP1 among the mRNA Binding Proteins that specifically target the X1 3′UTR in melanoma cells. Mechanistically, PARP1 Zinc Finger domain down-regulates BRAF expression at the translational level. As a consequence, it exerts a negative impact on MAPK pathway, and sensitizes melanoma cells to BRAF and MEK inhibitors, both in vitro and in vivo. In summary, our study unveils PARP1 as a negative regulator of the highly oncogenic MAPK pathway in melanoma, through the modulation of BRAF - X1 expression.
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia
Authors: Ignacio Martin-Loeches, Antoni Torres, Blin Nagavci, Stefano Aliberti, Massimo Antonelli, Matteo Bassetti, Lieuwe D. Bos, James D. Chalmers, Lennie Derde, Jan de Waele, Jose Garnacho-Montero, Marin Kollef, Carlos M. Luna, Rosario Menendez, Michael S. Niederman, Dmitry Ponomarev, Marcos I. Restrepo, David Rigau, Marcus J. Schultz, Emmanuel Weiss, Tobias Welte, Richard Wunderink
Journal: Intensive Care Medicine (2023)
Gut Microbiota–Derived Trimethylamine N-Oxide Contributes to Abdominal Aortic Aneurysm Through Inflammatory and Apoptotic Mechanisms
Authors: Tyler W. Benson, Kelsey A. Conrad, Xinmin S. Li, Zeneng Wang, Robert N. Helsley, Rebecca C. Schugar, Taylor M. Coughlin, Caris Wadding-Lee, Salma Fleifil, Hannah M. Russell, Timothy Stone, Michael Brooks, Jennifer A. Buffa, Kevin Mani, Martin Björck, Anders Wanhainen, Naseer Sangwan, Sudha Biddinger, Rohan Bhandari, Akiirayi Ademoya, Crystal Pascual, W.H. Wilson Tang, Michael Tranter, Scott J. Cameron, J. Mark Brown, Stanley L. Hazen, A. Phillip Owens
Journal: Circulation (2023)

Large-scale human and mechanistic mouse studies indicate a strong relationship between the microbiome-dependent metabolite trimethylamine N-oxide (TMAO) and several cardiometabolic diseases. This study aims to investigate the role of TMAO in the pathogenesis of abdominal aortic aneurysm (AAA) and target its parent microbes as a potential pharmacological intervention.